$500M Evergreen Fund
60+ Digital Health Investments
Investing globally in platform companies with proven technologies or business models where Merck's expertise can accelerate revenue growth and enhance value creation
Connecting innovative companies with complementary technologies to develop integrated healthcare solutions
Leveraging the vast R&D-based, global resources of Merck
Combining emerging informational tools with existing health data while leveraging Health IT platforms enables innovative solutions which can improve the quality of health outcomes achieved and lower overall health system costs
GHI Fund typically invests in the areas described below, with a focus on therapeutic areas aligned with Merck’s strengths in Oncology, CNS, Immunology and Virology.
THERAPY PLANNING - Ensuring delivery of the right treatment to the right patient at the right time. Utilizing Diagnostic & Patient Profiling solutions to identify undiagnosed patients, diagnose, and stratify patients. Providing Clinical Decision Support & Care Planning solutions enabling providers with expertise and precise relevant content, helping them make sense of data and provide individualized treatment recommendations.
CARE MANAGEMENT - Ensuring improved outcomes, lower costs, and improved patient satisfaction. Improving Care Coordination by making care plans understandable and manageable, as well as linking clinical data with behavioral data, creating a contextual feedback loop. Providing Patient Education & Engagement solutions to enable providers and patients to jointly achieve desired outcomes. Utilizing Population Health & Monitoring solutions to identify care gaps and improve quality of care while eliminating unnecessary costs.
HEALTH ANALYTICS & AI - Enabling better care by transforming big data into real world evidence through advanced analytics and self-learning platforms. Providing data interoperability, accessibility, and security to enable effective delivery of outcomes.
eCLINICAL TRIALS - Improving site selection and trial subject recruitment by leveraging advances in analytics and social engagement platforms. Improving protocol adherence, helping patients engage with the system before, during and after studies through advances in mobile platforms and remote monitoring technologies.
ENABLING TECHNOLOGIES - Innovative technologies and solutions with the potential to transform biopharmaceutical operations, including solutions for clinical operations, regulatory, pharmacovigilance, supply chain, enterprise architecture, sales and marketing. Also, selective early-stage investments in ‘next horizon’ technologies that have the potential to fundamentally disrupt scale economics of biopharmaceutical operations.
Typical venture investments have current revenue, are close to profitability, and are seeking growth capital.
Investing globally, with a focus on North America & Europe
Smallest Investment: $1.5M
Largest Investment: $35M
Hover over each logo for additional information
A team with deep expertise in digital health and healthcare operating experience
Providing expansion capital for existing businesses in a therapeutic and brand-agnostic manner
Streamlined investment process and autonomy to make deals
Expert guidance from an experienced, entrepreneurial senior leadership team
Incented to create value for our portfolio companies
Access to leading science, supply chain, commercial channel, marketing and regulatory experts
Connections to Merck’s global operations and talent in more than 140 countriesStrategic Partnering:
Facilitating collaborative relationships through Strategic Innovation Alliances function